Development of antiviral therapy for severe acute respiratory syndrome.

Cinatl, Jindrich and Michaelis, Martin and Hoever, Gerold and Preiser, Wolfgang and Doerr, Hans Wilhelm (2005) Development of antiviral therapy for severe acute respiratory syndrome. Antiviral Research, 66 (2-3). pp. 81-97. ISSN 0166-3542. (doi:https://doi.org/10.1016/j.antiviral.2005.03.002) (The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided)

The full text of this publication is not currently available from this repository. You may be able to access a copy if URLs are provided. (Contact us about this Publication)
Official URL
http://dx.doi.org/10.1016/j.antiviral.2005.03.002

Abstract

A new disease, the severe acute respiratory distress syndrome (SARS), caused by the SARS coronavirus (SARS-CoV), emerged at the beginning of 2003 and rapidly spread throughout the world. Although the disease had disappeared in June 2003 its re-emergence cannot be excluded. The development of vaccines against SARS-CoV may take years. Therefore, the availability of effective antiviral drugs against SARS-CoV may be crucial for the control of future SARS outbreaks. In this review, experimental and clinical data about potential anti-SARS drugs is summarised and discussed. Animal model studies will be needed to help to determine which interventions warrant controlled clinical testing.

Item Type: Article
Subjects: R Medicine > RM Therapeutics. Pharmacology
Divisions: Faculties > Sciences > School of Biosciences
Depositing User: Martin Michaelis
Date Deposited: 05 Jun 2013 20:37 UTC
Last Modified: 22 Apr 2014 11:21 UTC
Resource URI: https://kar.kent.ac.uk/id/eprint/34109 (The current URI for this page, for reference purposes)
  • Depositors only (login required):